Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
NCT04893148 on ClinicalTrials.gov · last registry update 2022-07-20
40 participants. The sponsor logged completion for 30 December 2021. Primary outcome, as filed: Changes in glycated hemoglobin (HbA1c). dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- dulaglutideTrulicity
- Sponsor
- Chungbuk National University Hospital
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2020-05-26
- Primary completion
- 2021-12-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Changes in glycated hemoglobin (HbA1c)
Conditions studied
Type 2 Diabetes Mellitus · Glucose, High Blood
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.